A Phase 2 Study Of The Safety And Efficacy Of Brepocitinib In Adults With Cutaneous Sarcoidosis (BEACON)

Overview

About this study

This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with cutaneous sarcoidosis.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

1. Adults subjects (18-74)
2. Cutaneous sarcoidosis with characteristic skin biopsy histology
3. A CSAMI activity score ≥ 10
4. Weight \> 40 kg to \< 130 kg with BMI \< 40 kg/m2 .

Exclusion Criteria

1. History of

* Lymphoproliferative disorder
* Active malignancy;
* History of cancer within 5 years prior to baseline (exceptions for basal cell carcinoma, squamous cell carcinoma, or carcinoma in situ of the uterine cervix).
2. High risk of thrombosis or cardiovascular disease
3. High risk of herpes zoster
4. Active or recent infection
Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 5/19/2025. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Aaron Mangold, M.D.

Open for enrollment

Contact information:

Brett Renner

(480) 301-9797

Renner.Brett@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20581310

Mayo Clinic Footer